Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 clinical guideline sources
9 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI108807

Concentration of l-Thyroxine and l-Triiodothyronine Specifically Bound to Nuclear Receptors in Rat Liver and Kidney: QUANTITATIVE EVIDENCE FAVORING A MAJOR ROLE OF T3 IN THYROID HORMONE ACTION

Martin I. Surks and Jack H. Oppenheimer

Endocrine Research Laboratory, Department of Medicine, Montefiore Hospital and Medical Center, Bronx, New York 10467

Division of Endocrinology, Department of Medicine, Montefiore Hospital and Medical Center, Bronx, New York 10467

Albert Einstein College of Medicine, Bronx, New York 10467

Find articles by Surks, M. in: JCI | PubMed | Google Scholar

Endocrine Research Laboratory, Department of Medicine, Montefiore Hospital and Medical Center, Bronx, New York 10467

Division of Endocrinology, Department of Medicine, Montefiore Hospital and Medical Center, Bronx, New York 10467

Albert Einstein College of Medicine, Bronx, New York 10467

Find articles by Oppenheimer, J. in: JCI | PubMed | Google Scholar

Published September 1, 1977 - More info

Published in Volume 60, Issue 3 on September 1, 1977
J Clin Invest. 1977;60(3):555–562. https://doi.org/10.1172/JCI108807.
© 1977 The American Society for Clinical Investigation
Published September 1, 1977 - Version history
View PDF
Abstract

To estimate the relative contribution of l-triiodothyronine (T3) and l-thyroxine (T4) to thyroidal effects, we have measured the concentration of iodothyronine bound to specific hepatic nuclear receptor sites by three different techniques: (a) specific radioimmunoassay after separation of T3 and T4 by preparative paper chromatography; (b) in vivo kinetic approaches as reported previously; and (c) isotopic equilibration. By these three methods, receptor concentration of T3 and T4 in liver was 0.51±0.19 (SD) and 0.08±0.06; 0.52±0.12 and 0.08±0.02; and 0.50±0.13 and 0.10±0.03 pmol/mg DNA, respectively. The percentage contribution of T3 and T4 to total receptor iodothyronine was thus 86.8±9.0 and 13.2±9.4; 86.3±3.5 and 13.7±3.5; and 83.7±5.6 and 16.3±5.6%, respectively. In kidney, specifically bound nuclear T3 and T4 were estimated both by isotopic equilibration and by in vivo kinetic techniques to be 0.28±0.11 and 0.03±0.01 pmol/mg DNA, respectively. Thus, T3 constituted 89.4±3.2% of total receptor iodothyronine in this tissue. No other iodothyronines or analogs were bound to the nuclear sites in either tissue. Kidney and liver nuclear T3 concentrations also were identical to values previously reported with in vivo kinetic techniques. Other studies from this laboratory have suggested that thyroid effect is related to the molar concentration of iodothyronine bound to specific nuclear sites, that the sites are similar in various tissues, and that iodothyronine in plasma is in equilibrium with nuclear T3. If these relationships are assumed, T3 contributes between 85 and 90% of thyroidal effects in the euthyroid rat. The remaining 10-15% of thyroidal effect appears to result from the intrinsic activity of T4.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 555
page 555
icon of scanned page 556
page 556
icon of scanned page 557
page 557
icon of scanned page 558
page 558
icon of scanned page 559
page 559
icon of scanned page 560
page 560
icon of scanned page 561
page 561
icon of scanned page 562
page 562
Version history
  • Version 1 (September 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 clinical guideline sources
9 readers on Mendeley
See more details